This week in drug discovery (3-7 June) 

News round-up for 3-7 June by DDW Senior Digital Content Editor Diana Spencer.

With the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting concluding this week, the headline news has all focused on breakthrough cancer research shared at the event.

The top stories:

New drug represents a ‘remarkable advancement’ in lung cancer

New data show that an unprecedented 60% of patients with advanced lung cancer given Lorbrena (lorlatinib) remain alive without disease progression after five years.

Immunotherapy prior to surgery a ‘game-changer’ for bowel cancer

Phase II trial results have shown the superiority of immunotherapy pembrolizumab over chemotherapy when given before bowel cancer surgery.

Cancer vaccine shows sustained improvement in survival rates

Cancer vaccine mRNA-4157 (V940) in combination with Keytruda reduced the risk of recurrence or death by 49% in patients with resected high-risk melanoma.

Ozempic reduces risk of 13 types of cancer

Patients taking semaglutide (the active ingredient in Wegovy and Ozempic) were 19% less likely to develop 13 obesity-related cancers, according to new data.

ASCO 2024 research highlights

As well as key findings with regards to lorlatinib for lung cancer, epcoritamab in follicular lymphoma, and pembrolizumab for bowel cancer, there were other significant study results revealed at ASCO.

Related Articles

Join FREE today and become a member
of Drug Discovery World

Membership includes:

  • Full access to the website including free and gated premium content in news, articles, business, regulatory, cancer research, intelligence and more.
  • Unlimited App access: current and archived digital issues of DDW magazine with search functionality, special in App only content and links to the latest industry news and information.
  • Weekly e-newsletter, a round-up of the most interesting and pertinent industry news and developments.
  • Whitepapers, eBooks and information from trusted third parties.
Join For Free